Published Date: 06 May 2025
A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that artificial intelligence (AI) could help detect interval breast cancers—those that develop between routine screenings—before ...
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
These Athletes Weren't Doping. Their Genes Made It Look Like They Did.
2.
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer
3.
Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.
4.
In cancer survivors, loneliness is associated with a higher risk of death.
5.
UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts
1.
The Importance of Maintaining Normal Calcium Levels in Your Body
2.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
3.
Exploring the Mysteries of MGUS: Uncovering the Causes and Treatments
4.
PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision
5.
Unlocking the Benefits of Eltrombopag: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation